The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9814731 B1

PDF
Full Text
Expired
Date of Patent:
Nov. 14, 2017

Filed:

Jan. 18, 2017
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Paul Talalay, Baltimore, MD (US);

Hua Liu, Baltimore, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/352 (2006.01); A61K 31/5685 (2006.01); A61K 31/145 (2006.01); A61K 31/05 (2006.01); A61K 31/122 (2006.01); A61K 31/135 (2006.01); A61K 31/341 (2006.01); A61K 31/165 (2006.01); A61K 31/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5685 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/122 (2013.01); A61K 31/135 (2013.01); A61K 31/145 (2013.01); A61K 31/165 (2013.01); A61K 31/341 (2013.01);
Abstract

In addition to its potent mechanism-dependent inhibition of estrogen biosynthesis, in accordance with the embodiments of the present invention, it has now been found that exemestane has novel chemoprotective properties which have hitherto not been explicitly recognized. The present invention provides methods for the use of compositions comprising exemestane for chemoprotection against a wide variety of non-mammary tumors (and possibly other chronic diseases) that are not estrogen-dependent, but have oxidative stress, inflammation and electrophile-damaging etiologies. The present invention also shows that exemestane shows powerful synergism with other classes of Nrf2-activators and phase 2 enzyme gene activators, including, for example sulforaphane (an isothiocyanate), shikonin (a naphthoquinone), zerumbone (a cyclic sesquiterpene) and resveratrol (a stilbene derivative), which increases the attractiveness of exemestane's novel uses.


Find Patent Forward Citations

Talalay, Paul. (2017). Method for the induction of phase 2 related genes in a mammal comprising administering exemestane (U.S. Patent No. 9814731). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9814731

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…